

Appointment of Interim Chief Executive Officer

Microba Life Sciences Limited (ASX: MAP) (Microba or the Company) advises that its Chief Executive Officer, Dr Luke Reid, is on medical leave. To provide leadership continuity, the Board has appointed Mr Geoffrey Cockerill as Interim Chief Executive Officer, commencing 29 September 2026.

About Mr Cockerill

Mr Cockerill is an experienced executive and company director with more than 30 years of leadership experience across large and complex organisations in Australia and internationally. His career has included senior leadership roles with Diageo Australia and Lion, and with Subway Systems, where he served as Regional Director for Australia, New Zealand and South-East Asia and as a member of the Global Executive Leadership Team.

Most recently, Mr Cockerill was Chief Executive Officer of ASX-listed Vitura Health Limited (ASX: VIT) and, before that, Chief Executive Officer of ATP Science. Across those roles he has led organisational transformation, operational improvement, cost and efficiency programs and commercial growth initiatives.

Mr Cockerill has completed the Australian Institute of Company Directors program and holds a Bachelor of Commerce, majoring in Marketing and Human Resources. He is based in Brisbane.

Key terms of engagement

In accordance with ASX Listing Rule 3.16.4, a summary of the material terms of the engagement are set out below.

Term	Summary
Position	Interim Chief Executive Officer, reporting to the Board through the Chair. Mr Cockerill is not a director of the Company or any of its subsidiaries.
Nature of engagement	Independent contractor
Term	Initial term of six months, which may be extended by agreement between the parties.
Fixed remuneration	A daily fee of \$2,100 (excluding GST), inclusive of superannuation, on the basis of five days per week.
Incentives	Mr Cockerill is not entitled to any short-term or long-term incentive, equity or equity-based award, or any completion, success or transaction-related fee.
Termination	Either party may terminate the engagement on four weeks' written notice. The Company may terminate immediately for cause.

This announcement has been authorised for release by the Board of Directors.

For further information, please contact:

Investor / Media Relations

investor@microba.com

<https://ir.microba.com/welcome>

About Microba Life Sciences Limited

Microba is at the forefront of microbiome health and human care. With world-leading science, insights and collaboration tools, Microba's vision is to deliver clinical-grade microbiome tests that help people live healthier, happier lives. Better science. Better insights. Better health. Microba - Expect better. www.microba.com



JOIN MICROBA'S INTERACTIVE INVESTOR HUB

For more Company information and to engage with management by asking questions about Microba's latest announcements and updates, visit ir.microba.com/welcome

Microba Life Sciences Ltd | ABN 82 617 096 652 | L10, 324 Queen Street, Brisbane QLD 4000 Australia | 1300 974 621